An amalgamation of strategies, marketing, and competitive intelligence (CI) for pharma, devices and diagnostic companies that are planning to introduce or check the adequate supply of products amid the market competition and price war.
Healthcare market access involves real-time tracking of market nuances and reality checks, before any product entry, pricing adjustments, product landscaping, or competitor mapping.
We help you address these questions before you plan the process.
How do I use high volume data to understand the payer dynamics?
What do I need to obtain optimal reimbursement in every state of the US?
Where do I disseminate market insights?
Why are my peers doing better than me in certain markets?
How do I maximize the value of my products/drugs/equipment to the payers?
Be it a startup or an established player in the market, one can never be sure of the customer’s or decisionmaker’s mood in the market. One needs a real-time check on whether their products are reaching the high-demand market or getting stock-piled in warehouses.
We have supported key Korean and Indonesian companies to enter the US, and supported family-run medical diagnostic businesses entering western Europe. Our credibility and visibility in the market can be validated by our growing number of offices globally.
SGA covers both native English speaking and non-English speaking markets like the GCC, CIS, SEA, and LATAM.
SGA offers a 360° overview of pricing and market access systems and tracks how the key country pricing systems work before planning your market entry or expansion.
SGA’s experts on systematic literature review, evaluate, and advise why setting prices with health economics is not the same as defending prices with health economics in each market.
SGA measures the strength of your clinical profile and the ‘pricing power’ it affords you by conducting market surveys and primary research with end users.
SGA uses evidence-based techniques to get the most accurate feedback while conducting pricing research with the payers. Our insights are stronger and better as our pool size of customer interviewees is statistically significant and driven by our in-house panelists.
SGA analyzes historic payer behavior and current nuances as a powerful predictor and explainer of future pricing behavior. Our forecast models are customizable and data-driven and built by industry experts who have more than 15 years of experience in their specific fields.
SGA’s global network helps you evaluate the impact of your product’s prices globally.
Our team of experts supports your market access teams during the implementation phase and helps build a sustainable near-term roadmap.
Why SGA
Industry Leaders
SGA thrives by its brand promise - Life is Possible, and is recognized as the trusted healthcare market research consulting company in the USA.
12+ Languages
Language capabilities include Mandarin, Cantonese, Korean, German, Spanish, Arabic, Bahasa, Hindi, Bengali, and English experts (US/UK).
Data-Driven Insights
With in-depth domain knowledge and proven capabilities of delivering monetizable insights, we deliver high-quality, efficient outputs.
End-To-End Solutioning
The in-house KOL capability of more than 700, along with analytical and ML/AI capabilities, helps in presenting credible competitive information.
Whitepapers
Market Entry in 2023: Why Must You Also Look at Markets Other Than the US and Japan?
Due to dollar fluctuations and the likelihood of market recession, investors and manufacturers of medical devices and pharma are exploring new opportunities...
Whitepapers
The Blue Ocean Strategy in the Pharmaceutical Industry: What Is the Blue Ocean Strategy About?
Blue ocean refers to a new market that presents low competition, is less crowded, and is open to accommodate new innovations and marketing opportunities....
Whitepapers
What Happens When You Invest in Healthcare Consulting and Analytics?
Healthcare providers who are struggling with high-volume complex data are feeling the need for assistance with data convergence and management. With...
We strongly believe in women power. Our research team consists of more females than males i.e., 55 % females, and consists of PhDs, M Pharms, D Pharms, Postgraduate in finance, Biotech postgraduates, and MBAs.
